These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Treatment options for Graves' orbitopathy. Marcocci C; Altea MA; Leo M Expert Opin Pharmacother; 2012 Apr; 13(6):795-806. PubMed ID: 22404364 [TBL] [Abstract][Full Text] [Related]
44. [Diagnosis and treatment of dysthyroid orbitopathy: a multidisciplinary disease]. Leray B; Imbert P; Thouvenin D; Boutault F; Caron P J Fr Ophtalmol; 2013 Dec; 36(10):874-85. PubMed ID: 24239215 [TBL] [Abstract][Full Text] [Related]
45. The effects of Rituximab on Graves'orbitopathy: A retrospective study of 14 patients. Eid L; Coste-Verdier V; Longueville E; Ribeiro E; Nicolescu-Catargi B; Korobelnik JF Eur J Ophthalmol; 2020 Sep; 30(5):1008-1013. PubMed ID: 31025590 [TBL] [Abstract][Full Text] [Related]
46. Future Prospects for the Treatment of Graves' Hyperthyroidism and Eye Disease. Neumann S; Place RF; Krieger CC; Gershengorn MC Horm Metab Res; 2015 Sep; 47(10):789-96. PubMed ID: 26197854 [TBL] [Abstract][Full Text] [Related]
47. Low-Dose Rituximab for Active Moderate to Severe Graves' Orbitopathy Resistant to Conventional Treatment. Du Pasquier-Fediaevsky L; Andrei S; Berche M; Leenhardt L; Héron E; Rivière S Ocul Immunol Inflamm; 2019; 27(5):844-850. PubMed ID: 29652204 [No Abstract] [Full Text] [Related]
48. Clinical Features of Graves' Ophthalmopathy and Impact of Enalapril on the Course of Mild Graves' Ophthalmopathy: A Pilot Study. Ataabadi G; Dabbaghmanesh MH; Owji N; Bakhshayeshkaram M; Montazeri-Najafabady N Endocr Metab Immune Disord Drug Targets; 2020; 20(1):139-148. PubMed ID: 31345156 [TBL] [Abstract][Full Text] [Related]
52. Graves' Orbitopathy: Current Concepts for Medical Treatment. Oeverhaus M; Stöhr M; Möller L; Führer D; Eckstein A Klin Monbl Augenheilkd; 2021 Jan; 238(1):24-32. PubMed ID: 33506447 [TBL] [Abstract][Full Text] [Related]
53. Effect of tanshinone IIA in an in vitro model of Graves' orbitopathy. Rhiu S; Chae MK; Lee EJ; Lee JB; Yoon JS Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):5900-10. PubMed ID: 25159204 [TBL] [Abstract][Full Text] [Related]
54. Selenium in Graves Hyperthyroidism and Orbitopathy. Marinò M; Menconi F; Rotondo Dottore G; Leo M; Marcocci C Ophthalmic Plast Reconstr Surg; 2018; 34(4S Suppl 1):S105-S110. PubMed ID: 29933354 [TBL] [Abstract][Full Text] [Related]
56. Novel observational study protocol to develop a prediction model that identifies patients with Graves' ophthalmopathy insensitive to intravenous glucocorticoids pulse therapy. Wang Y; Wang H; Li L; Li Y; Sun J; Song X; Zhou H BMJ Open; 2021 Dec; 11(12):e053173. PubMed ID: 34916318 [TBL] [Abstract][Full Text] [Related]
57. Pediatric Graves' ophthalmopathy: the pre- and postpubertal experience. Holt H; Hunter DG; Smith J; Dagi LR J AAPOS; 2008 Aug; 12(4):357-60. PubMed ID: 18359653 [TBL] [Abstract][Full Text] [Related]
58. Natural course of mild Graves' orbitopathy: is it a chronic remitting or a transient disease? Anagnostis P; Boboridis K; Adamidou F; Kita M J Endocrinol Invest; 2017 Mar; 40(3):257-261. PubMed ID: 27664101 [TBL] [Abstract][Full Text] [Related]
59. Orbital decompression in Graves' orbitopathy: efficacy and safety. Goh MS; McNab AA Intern Med J; 2005 Oct; 35(10):586-91. PubMed ID: 16207257 [TBL] [Abstract][Full Text] [Related]